The specialist cancer drug discovery and development business has conducted a successful fundraising of £681k at 0.4p. The recently appointed Non-executive Director Clive Birch subscribed for 1.25m shares at the placing price. The net proceeds will be used to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes.
26 Jun 2019
£0.68m raised to progress TYK2/JAK1 assets towards the clinic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
£0.68m raised to progress TYK2/JAK1 assets towards the clinic
Sareum Holdings plc (SAR:LON) | 27.2 -0.9 (-10.7%) | Mkt Cap: 28.5m
- Published:
26 Jun 2019 -
Author:
Derren Nathan -
Pages:
6
The specialist cancer drug discovery and development business has conducted a successful fundraising of £681k at 0.4p. The recently appointed Non-executive Director Clive Birch subscribed for 1.25m shares at the placing price. The net proceeds will be used to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes.